A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients (MACH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01805895
Recruitment Status : Unknown
Verified February 2016 by Jeffrey Switzer, Georgia Regents University.
Recruitment status was:  Recruiting
First Posted : March 6, 2013
Last Update Posted : February 10, 2016
American Heart Association
Information provided by (Responsible Party):
Jeffrey Switzer, Georgia Regents University

Brief Summary:
The MACH Trial is a pilot study of 400mg minocycline over five days in acute intracerebral hemorrhage patients. The study will evaluation the safety and efficacy of minocycline in intracerebral hemorrhage patients.

Condition or disease Intervention/treatment Phase
Intracerebral Hemorrhage Drug: Minocycline Phase 1 Phase 2

Detailed Description:
MACH is a randomized trial of minocycline in intracerebral hemorrhage. 24 total subjects will be randomly assigned to minocycline or control (1:1). The first dose will be given intravenously. Subsequent doses will be given orally every 24 hours for a total of five doses. The study will test to see if the medication is safe in intracerebral hemorrhage. The pharmacokinetics of minocycline in intracerebral hemorrhage will be determined and the impact of minocycline on blood biomarkers.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Minocycline in Acute Cerebral Hemorrhage (MACH) Trial
Study Start Date : February 2013
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : March 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Minocycline
This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
Drug: Minocycline
This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
Other Name: Dynacin, Minocin
No Intervention: Control
This arm will not receive any minocycline. This arm will receive standard of care treatment.

Primary Outcome Measures :
  1. modified Rankin Scale [ Time Frame: 90 days ]
    A blinded assessor will perform the modified Rankin Scale after 90 days to determine functional outcome. This will serve as our efficacy endpoint.

Secondary Outcome Measures :
  1. Safety Assessment [ Time Frame: 90 days ]
    Adverse events will be asses for 90 days. This will serve as our safety endpoint.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older.
  • Intracerebral hemorrhage documented by CT scan
  • The first dose of the drug can be administered within 12 hours of time last known to be at baseline

Exclusion Criteria:

  • Allergy to tetracycline antibiotics
  • Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
  • Hepatic and/or renal insufficiency (LFT's >3x upper limit of normal; Creatinine >2mg/dL)
  • History of intolerance to minocycline
  • National Institutes of Health Stroke Scale score of 4 or less
  • Glasgow Coma Scale score of 5 or less
  • Surgical evacuation of hematoma planned within 24 hours
  • Secondary intracerebral hemorrhage resulting from trauma, arteriovenous malformation, aneurysm, tumor or other causes
  • Thrombocytopenia (platelet count <75,000/mm3) or coagulopathy (INR >1.4)
  • Previously not independent (prestroke modified Rankin scale score >2)
  • Suspected of not being able to comply with the study protocol
  • Unlikely to be available for 90 day follow-up
  • Pre-existing Do Not Resuscitate (DNR) order or indication that a new DNR order will be implemented within the first 48 hours of hospitalization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01805895

Contact: Jeffrey A Switzer, DO 706-721-1691
Contact: Mary Anne Park, RN 706-721-0193

United States, Georgia
Georgia Health Sciences University Recruiting
Augusta, Georgia, United States, 30912
Contact: Jeffrey Switzer, DO    706-721-1691   
Principal Investigator: Jeffrey Switzer, DO         
Sub-Investigator: David Hess, MD         
Sub-Investigator: Askiel Bruno, MD         
Sub-Investigator: Fenwick Nichols, MD         
Sub-Investigator: Hartmut Gross, MD         
Sub-Investigator: Susan Fagan, PharmD         
Sponsors and Collaborators
Augusta University
American Heart Association
Principal Investigator: Jeffrey A Switzer, DO Augusta University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jeffrey Switzer, Associate Professor, Georgia Regents University Identifier: NCT01805895     History of Changes
Other Study ID Numbers: Pro00000718
First Posted: March 6, 2013    Key Record Dates
Last Update Posted: February 10, 2016
Last Verified: February 2016

Keywords provided by Jeffrey Switzer, Georgia Regents University:
Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage
Hemorrhagic stroke

Additional relevant MeSH terms:
Cerebral Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents